Phase 1, open-label study of MEDI-547 in patients with relapsed or refractory solid tumors.

ABSTRACT:

Background

Targeting the cell-surface receptor EphA2, which is highly expressed in some solid tumors, is a novel approach for cancer therapy. We aimed to evaluate the safety profile, maximum tolerated dose (MTD), pharmacokinetics, and antitumor activity of MEDI-547, an antibody drug conjugate composed of the cytotoxic drug auristatin (toxin) linked to a human anti-EphA2 monoclonal antibody (1C1), in patients with solid tumors relapsed/refractory to standard therapy.

Methods

In this phase 1, open-label study with planned dose-escalation and dose-expansion cohorts, patients received a 1-h intravenous infusion of MEDI-547 (0.08 mg/kg) every 3 weeks.

Results

Six patients received 0.08 mg/kg; all discontinued treatment. Dose escalation was not pursued. The study was stoppe

SUBMITTER: Annunziata CM 

PROVIDER: S-EPMC3553417 | biostudies-literature | 2013 Feb

REPOSITORIES: biostudies-literature